LinagliptinA Review of its Use in the Management of Type 2 Diabetes Mellitus

被引：0
作者：
Emma D. Deeks
机构：
[1] Adis,
来源：
Drugs | 2012年 / 72卷
关键词：
Metformin; Pioglitazone; Glycaemic Control; Sulfonylurea; Sitagliptin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Linagliptin (Trajenta®, Tradjenta™, Trazenta™, Trayenta™) is an oral, highly selective inhibitor of dipeptidyl peptidase-4 and is the first agent of its class to be eliminated predominantly via a nonrenal route. Linagliptin is indicated for once-daily use for the treatment of adults with type 2 diabetes mellitus, and a twice-daily fixed-dose combination of linagliptin/metformin (Jentadueto®) is lso available. In this article, the pharmacological, clinical efficacy and tolerability data relevant to the use of linagliptin in patients with type 2 diabetes are reviewed.
引用
收藏
页码：1793 / 1824
页数：31
相关论文
共 144 条
[1]  
Davidson J.A.(2009)Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors Clev Clin J Med 76 S28-38
[2]  
Tahrani A.A.(2011)Management of type 2 diabetes: new and future developments in treatment Lancet 378 182-97
[3]  
Bailey C.J.(2011)Type 2 diabetes across generations: from pathophysiology to prevention and management Lancet 378 169-81
[4]  
Del Prato S.(2007)The role of gut hormones in glucose homeostasis J Clin Invest 117 24-32
[5]  
Nolan C.J.(2012)Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants Clin Drug Investig 32 1-14
[6]  
Damm P.(2011)Linagliptin: in type 2 diabetes mellitus Drugs 71 611-24
[7]  
Prentki M.(2011)Effect of linagliptin monotherapy on glycaemic control and markers of b-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial Diabetes Obes Metab 13 258-67
[8]  
Drucker D.J.(2012)Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study Diabetes Obes Metab 14 348-57
[9]  
Holst J.J.(2010)Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes Diabet Med 27 1409-19
[10]  
McGill M.A.(2011)Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes Obes Metab 13 65-74
12345678910